Abstract |
Although increasing levels of glucose-6-phosphate dehydrogenase (G6PD) have been widely reported in human breast tumor tissue, the effects of 17 beta-estradiol and progesterone on this key enzyme of cellular growth processes have not been well documented. Cellular heterogeneity of breast tumor tissue, coupled with the low sensitivity of classical biochemical assays of G6PD, are the main sources of difficulties in these studies. In the present report, the effects of estradiol and a progesterone analogue ( R5020) on G6PD activity were studied using the MCF-7 cell line and a cytochemical assay of G6PD activity. Our results show that: (a) this assay can be used to perform quantitative measurements of G6PD on individual cells using small number of cells (20-30); and (b) both estradiol (10(-8)-10(-5) M) and R5020 (10(-9)-10(-5) M) stimulate the G6PD activity in dividing MCF-7 cells. Maximal stimulation (20-30%) was obtained after 24 h of treatment. This combination of MCF-7 cells and cytochemical assay is suitable for further studies on the effects of estradiol and R5020 stimulation of G6PD activity in breast tumors.
|
Authors | J D Monet, M Thomas, N Dautigny, M Brami, C A Bader |
Journal | Cancer research
(Cancer Res)
Vol. 47
Issue 19
Pg. 5116-9
(Oct 01 1987)
ISSN: 0008-5472 [Print] United States |
PMID | 3621197
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Norpregnadienes
- NAD
- Estradiol
- Promegestone
- Glucosephosphate Dehydrogenase
|
Topics |
- Breast Neoplasms
(enzymology)
- Cell Division
- Cells, Cultured
- Estradiol
(pharmacology)
- Female
- Glucosephosphate Dehydrogenase
(analysis)
- Histocytochemistry
- Humans
- Kinetics
- NAD
(analysis)
- Norpregnadienes
(pharmacology)
- Promegestone
(pharmacology)
|